Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.94 - $1.23 $3,417 - $4,472
3,636 Added 40.58%
12,596 $12,000
Q2 2023

Aug 14, 2023

BUY
$1.1 - $1.54 $9,856 - $13,798
8,960 New
8,960 $10,000
Q2 2022

Aug 15, 2022

SELL
$1.34 - $5.34 $5.61 Million - $22.4 Million
-4,188,653 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $1.62 Million - $2.4 Million
-352,700 Reduced 7.77%
4,188,653 $19.2 Million
Q4 2021

Feb 14, 2022

BUY
$5.23 - $7.18 $2.04 Million - $2.81 Million
390,954 Added 9.42%
4,541,353 $29.2 Million
Q3 2021

Nov 15, 2021

BUY
$5.94 - $8.75 $5.75 Million - $8.47 Million
967,507 Added 30.4%
4,150,399 $25.7 Million
Q2 2021

Aug 16, 2021

SELL
$7.54 - $9.79 $10.6 Million - $13.7 Million
-1,399,980 Reduced 30.55%
3,182,892 $25.5 Million
Q1 2021

May 17, 2021

BUY
$4.76 - $11.25 $21.8 Million - $51.6 Million
4,582,872 New
4,582,872 $44.2 Million
Q3 2020

Nov 16, 2020

SELL
$2.3 - $3.72 $1.44 Million - $2.33 Million
-625,929 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$1.33 - $3.63 $497,514 - $1.36 Million
-374,071 Reduced 37.41%
625,929 $1.94 Million
Q1 2020

May 15, 2020

BUY
$1.27 - $2.33 $1.27 Million - $2.33 Million
1,000,000 New
1,000,000 $1.44 Million
Q3 2019

Nov 15, 2019

SELL
$1.93 - $4.21 $570,546 - $1.24 Million
-295,620 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.05 - $4.32 $606,021 - $1.28 Million
295,620 New
295,620 $1.28 Million
Q1 2019

May 15, 2019

SELL
$1.79 - $3.12 $1.79 Million - $3.12 Million
-1,000,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$3.58 - $4.9 $3.58 Million - $4.9 Million
1,000,000 New
1,000,000 $3.89 Million

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.